Two Sigma Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Two Sigma Securities’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-54,612	Closed	-$328K	–	3516
2022 Q4	$328K	Buy	+54,612	New	+$298K	0.01%	1451
2022 Q2	–	Sell	-18,472	Closed	-$86K	–	3019
2022 Q1	$86K	Buy	+18,472	New	+$55.1K	﹤0.01%	1824
2020 Q4	–	Sell	-23,248	Closed	-$50K	–	2077
2020 Q3	$50K	Buy	+23,248	New	+$29.7K	﹤0.01%	1206
2019 Q2	–	Sell	-12,091	Closed	-$12K	–	2579
2019 Q1	$12K	Buy	+12,091	New	+$12.7K	﹤0.01%	1724
2017 Q1	–	Sell	-6,042	Closed	-$24K	–	1256
2016 Q4	$24K	Buy	6,042 +2,314	+62%	+$9.6K	0.01%	645
2016 Q3	$14K	Buy	+3,728	New	+$13.6K	﹤0.01%	617
2015 Q3	–	Sell	-1,999	Closed	-$39K	–	330
2015 Q2	$39K	Buy	+1,999	New	+$38.6K	0.07%	135

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Securities's CTIC Position: Q1 2023 in Review

Two Sigma Securities sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 54,612 shares — an estimated $328K sold.

Two Sigma Securities first reported a position in CTIC in Q2 2015 and held it in 7 quarters. The position peaked at $328K in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Two Sigma Securities reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Two Sigma Securities sold 54,612 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $328K.
Two Sigma Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2015 and held it in 7 quarters.
Two Sigma Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $328K in Q4 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Two Sigma Securities's 13F filing for Q1 2023, filed 15 May 2023.